



Episurf Medical's 100th Episealer® Femoral Twin implant demonstrates rapid clinical adoption

Episurf Medical (NASDAQ: EPIS B) announces the 100th implantation of the knee implant Episealer Femoral Twin, which together with Episealer Condyle Solo and Episealer Trochlea Solo constitute Episurf Medical's product portfolio of patient-specific knee implants. This personalised treatment solution was developed to treat patients presenting with larger areas and an elongated nature of chondral and osteochondral damage of the femoral condyles and trochlea area of the knee.

"According to theory, a knee in need of an Episealer Twin implant is often somewhat more damaged, possibly further along the development of osteoarthritis, compared to a knee with the need of an Episealer Solo implant. We are very happy that also these larger lesions respond well to the Episealer and that we can successfully help patients with more challenging lesions. This is reassuring", says Professor Leif Ryd, Senior Medical Advisor to Episurf Medical.

In August 2017, Episurf Medical announced that the 250th implantation of the Episealer knee implant had been scheduled, which in addition to the Femoral Twin implant, also includes the Episealer Condyle Solo and Episealer Trochlea Solo implants.

For more information, please contact:

Pål Ryfors, CEO, Episurf Medical

Tel: +46 (0) 709 62 36 69

Email: pal.ryfors@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical's Episealer® personalized implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical's µFidelity® system enables implants to be cost-efficiently tailored to each individual's unique injury for the optimal fit and minimal intervention. Episurf Medical's head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company's website: www.episurf.com.

This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CEST on 14 September 2017.